Opinion|Videos|October 18, 2024
Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results
Key Takeaways
- Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response.
- Long-term follow-up data offer valuable insights into the sustained efficacy and safety of lupus nephritis treatments.
Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.
Episodes in this series
- How do you monitor patients with lupus nephritis for disease progression and treatment response? (Dr. Larranaga)
- Three-year follow-up results of voclosporin from the AURORA-2 study were
published earlier this year. What is the value of long-term follow-up data such as these in lupus nephritis? (Dr. Wells)
Related to this article
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
5